Jason Bock, PhD, is a biotech leader with a track record of building organizations that translate cutting-edge science into impactful biologic therapies. In 2019, he joined MD Anderson to establish the Biologics Development group, an internal biotech initiative focused on advancing MDACC-invented biologics. Under his leadership, the group spun off into CTMC in May 2022—a joint venture between MD Anderson Cancer Center and Resilience—where he now serves as CEO.
CTMC was founded to bridge innovative academic discoveries with industrial drug development and advanced manufacturing, accelerating the path of transformative cell therapies to patients. Headquartered in a 60,000 SF cell therapy manufacturing facility in the Texas Medical Center, CTMC houses 14 cleanrooms, process and analytical labs, and office space only steps from MD Anderson’s main campus. Since its launch, CTMC has successfully guided eight novel cell therapies through IND clearance.
Prior to CTMC, Dr. Bock was Site Head and VP of Global CMC Biologics in Teva Pharmaceuticals’ Specialty R&D Division. Over a decade at Teva, he expanded the Biologics team to 600+ employees, advanced 15 novel drugs from preclinical to clinical development, and led three biologics through the clinic to global commercialization. He joined Teva via its acquisition of CoGenesys, a biotech spin-out from Human Genome Sciences (HGS), where he began his career. Dr. Bock holds a BS in Biology from MIT and a PhD in Molecular and Cellular Physiology from Stanford University.